Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B013 plus albumin-bound paclitaxel in first-line TNBC
CTR20222396Phase 3Completed
- Sponsor
- Shanghai Cross-linked Pharmaceutical Research and Development
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of B-013 in triple-negative breast cancer (TNBC), sponsored by Shanghai Cross-linked Pharmaceutical Research and Development. Started Sep 2022; status: completed.
02
Drugs
B-013
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20222396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222396.